Compare WTFC & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTFC | IBRX |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.4B |
| IPO Year | N/A | 2015 |
| Metric | WTFC | IBRX |
|---|---|---|
| Price | $136.53 | $8.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | ★ $164.14 | $12.57 |
| AVG Volume (30 Days) | 385.9K | ★ 26.4M |
| Earning Date | 04-20-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $13.65 | $88.59 |
| Revenue Next Year | $6.33 | $131.15 |
| P/E Ratio | $13.60 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $89.31 | $1.83 |
| 52 Week High | $162.96 | $12.43 |
| Indicator | WTFC | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.61 | 50.22 |
| Support Level | $127.48 | $7.77 |
| Resistance Level | $142.32 | $8.28 |
| Average True Range (ATR) | 3.20 | 0.85 |
| MACD | 0.66 | -0.18 |
| Stochastic Oscillator | 71.31 | 55.83 |
Wintrust Financial Corp is a financial holding company that provides community-oriented, personal, and commercial banking services to customers generally located in the Chicago metropolitan area, southern Wisconsin, northwest Indiana, and western Michigan. The company provides specialty finance services, including financing for the payment of property and casualty insurance premiums and life insurance premiums, and wealth management services to customers in its market area. The company's operations consist of three primary segments: community banking, specialty finance, and wealth management. The company generates the majority of its revenue from the community banking segment.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.